Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Liabilities

v3.23.2
Accrued Expenses and Other Liabilities
6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Accrued Expenses and Other Liabilities

Note 7 – Accrued Expenses and Other Liabilities

 

Accrued Expenses, summarized by major category, as of June 30, 2023 and December 31, 2022 consist of the following:

 

    June 30, 2023     December 31, 2022  
Payroll and incentives   $ 1,027     $ 1,705  
General and administrative expenses     257       455  
Research and development expenses     88       130  
Deferred revenue *     -       721  
Other deferred liabilities **     -       88  
Total   $ 1,372     $ 3,099  

 

  * At December 31, 2022, the balance included $688 related to an exclusive research collaboration with BioNTech SE (the “BioNTech Agreement”) and $33 related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”). (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).
     
  ** At December 31, 2022, the balances of $88 related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement). (See Note 9 – Revenue Recognition, Collaboration Agreements and Other).